STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Science Corporation announced Wednesday that European regulators approved commercial sale of its retinal implant for patients with age-related macular degeneration affecting central vision
- The retinal implant improves vision enough for patients to read books and road signs more clearly, according to the company
- Founder and CEO Max Hodak called the device "a cochlear implant for vision now," framing it as a parallel breakthrough to auditory prosthetics
- The device could launch in the United States in 2027, putting American AMD patients on a near-term path to accessing the same implant now cleared in Europe
Why it matters: Age-related macular degeneration robs patients of central vision, leaving limited options beyond magnification and injection drugs. A commercial implant that restores functional sight — reading books, reading road signs — would be the first device-level restoration of lost vision for this population. With European clearance already secured and a 2027 U.S. target, the timeline for American access is now concrete enough to plan around.
